Literature DB >> 30133309

Biodistribution and Internal Radiation Dosimetry of 99mTc-IDA-D-[c(RGDfK)]2 (BIK-505), a Novel SPECT Radiotracer for the Imaging of Integrin αvβ3 Expression.

Yoo Sung Song1, Joong Hyun Kim2, Byung Chul Lee1,3, Jae Ho Jung1, Hyun Soo Park1,4, Sang Eun Kim1,3,4.   

Abstract

BACKGROUND: Integrin αvβ3 is a molecular marker for the estimation of tumor angiogenesis. 99mTc-IDA-D-[c(RGDfK)]2 (also known as BIK-505) is a recently developed radiotracer for single-photon emission computed tomography, with good affinity for integrin αvβ3. In this study, the authors investigated the whole-body distribution and internal radiation dosimetry of 99mTc-IDA-D-[c(RGDfK)]2 in elderly human participants.
MATERIALS AND METHODS: Six healthy volunteers underwent whole-body simultaneous anterior and posterior scans, preceded by transmission scans using cobalt-57 flood source, with a dual head gamma camera system, at 0, 1, 2, 4, 8, and 24 h postinjection of 99mTc-IDA-D-[c(RGDfK)]2 (injected radioactivity [mean ± SD] = 388.7 ± 29.3 MBq). Anterior and posterior images were geometrically averaged and attenuation corrected to delineate the regions of interest in the liver, gallbladder, kidneys, urinary bladder, spleen, brain, and large intestine. Radiation dose for each organ and the effective doses (EDs) were estimated using OLINDA/EXM 1.1 software.
RESULTS: High radiation doses of renal and biliary excretion tracks such as the urinary bladder wall, upper large intestine, kidneys, liver, and gallbladder wall (19.15 ± 6.84, 19.28 ± 4.78, 15.67 ± 0.90, 9.13 ± 1.71, and 9.09 ± 2.03 μGy/MBq, respectively) were observed. The ED and effective dose equivalent were 5.08 ± 0.53 and 7.11 ± 0.58 μSv/MBq, respectively.
CONCLUSIONS: Dosimetry results were comparable to other radiolabeled peptides and were considered safe and efficient for clinical usage.

Entities:  

Keywords:  99mTc-IDA-D-[c(RGDfK)]2; angiogenesis; biodistribution; dosimetry; integrin αvβ3 expression

Mesh:

Substances:

Year:  2018        PMID: 30133309      PMCID: PMC6241326          DOI: 10.1089/cbr.2018.2505

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  27 in total

1.  Biodistribution and dosimetry of TRODAT-1: a technetium-99m tropane for imaging dopamine transporters.

Authors:  P D Mozley; J B Stubbs; K Plössl; S H Dresel; E D Barraclough; A Alavi; L I Araujo; H F Kung
Journal:  J Nucl Med       Date:  1998-12       Impact factor: 10.057

2.  [68Ga]NODAGA-RGD for imaging αvβ3 integrin expression.

Authors:  Peter A Knetsch; Milos Petrik; Christoph M Griessinger; Christine Rangger; Melpomeni Fani; Christian Kesenheimer; Elisabeth von Guggenberg; Bernd J Pichler; Irene Virgolini; Clemens Decristoforo; Roland Haubner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-13       Impact factor: 9.236

Review 3.  Radiolabelled RGD peptides for imaging and therapy.

Authors:  F C Gaertner; H Kessler; H-J Wester; M Schwaiger; A J Beer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

4.  2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokinetics.

Authors:  Jiyun Shi; Young-Seung Kim; Sudipta Chakraborty; Bing Jia; Fan Wang; Shuang Liu
Journal:  Bioconjug Chem       Date:  2009-07-15       Impact factor: 4.774

5.  [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates.

Authors:  Roland Haubner; Bertrand Kuhnast; Christian Mang; Wolfgang A Weber; Horst Kessler; Hans-Jürgen Wester; Markus Schwaiger
Journal:  Bioconjug Chem       Date:  2004 Jan-Feb       Impact factor: 4.774

Review 6.  Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies.

Authors:  Roland Haubner; Hans-Jürgen Wester
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

7.  Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG.

Authors:  Ambros J Beer; Sylvie Lorenzen; Stephan Metz; Ken Herrmann; Petra Watzlowik; Hans-Jürgen Wester; Christian Peschel; Florian Lordick; Markus Schwaiger
Journal:  J Nucl Med       Date:  2007-12-12       Impact factor: 10.057

8.  Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers.

Authors:  Jiyun Shi; Young-Seung Kim; Shizhen Zhai; Zhaofei Liu; Xiaoyuan Chen; Shuang Liu
Journal:  Bioconjug Chem       Date:  2009-04       Impact factor: 4.774

9.  (99m)Tc-3P-RGD2 SPECT to monitor early response to bevacizumab therapy in patients with advanced non-small cell lung cancer.

Authors:  Bin Chen; Guoqing Zhao; Qingjie Ma; Bin Ji; Tiefeng Ji; Hua Xin; Shi Gao
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

10.  Requirement of vascular integrin alpha v beta 3 for angiogenesis.

Authors:  P C Brooks; R A Clark; D A Cheresh
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

View more
  2 in total

Review 1.  Surface-modified nanotherapeutics targeting atherosclerosis.

Authors:  Wenpan Li; Karina Marie Gonzalez; Jinha Chung; Minhyeok Kim; Jianqin Lu
Journal:  Biomater Sci       Date:  2022-09-27       Impact factor: 7.590

2.  Experimental evaluation of absolute quantification in 99m Tc-TRODAT-1 SPECT/CT brain dopamine transporter (DAT) studies.

Authors:  Norasma Amira Zainudin; Nadiah Zulkifli; Khadijah Hamid; Hazlin Hashim; Syahir Mansor
Journal:  J Appl Clin Med Phys       Date:  2022-07-14       Impact factor: 2.243

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.